Stevanato Group S.p.a. · NYSE:STVN
Stevanato — Q1 2026 Earnings Presentation
21 slides from Stevanato's earnings presentation, May 7, 2026
Slide 1: Stevanato Group Q1 2026 Financial Results
Exhibit 99.1 Stevanato Group Q1 2026 Financial Results May 7, 2026
Slide 2: Safe Harbor Statement
Safe Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of Stevanato Group S.p.A. (“we”, “our”, “us”, “Stevanato Group” or the “Company”) a
Slide 3: Stevanato Group Q1 2026 Financial Results Earnings Call
Stevanato Group Q1 2026 Financial Results Earnings Call Marco Lisa Dal Lago Miles CFO CCO and IR Q1 2026 Financial Results 3
Slide 4: Lisa Miles
x Lisa Miles Chief Communications & Investor Relations Officer On behalf of Franco Stevanato, Chief Executive Officer Q1 2026 Financial Results
Slide 5: Started 2026 with Strong Momentum Highlighted by 10% Revenue Growth at Constant Currency
Started 2026 with Strong Momentum Highlighted by 10% Revenue Growth at Constant Currency Continued Strong Demand in BDS Trends driving demand for RTU & Bulk Cartridges for (i) GLPs and • In Q1 2026, revenue growth driven by BDS Segment, and Incretin therapies, and (ii) other biologics, like mAbs not
Slide 6: Engineering Segment
Engineering Segment As anticipated, revenue declined and margins Team squarely focused on two main priorities improved yoy • First: continued execution of the business optimization plan • Gaining traction from Business Optimization Plan − Improved operational efficiency over the last 18 months − Rig
Slide 7: Demand-Driven Capacity Expansion Update
Demand-Driven Capacity Expansion Update Fishers (IN), U.S. Latina, Italy Supporting U.S. customers across the full value chain, Diversifying EMEA footprint with expanding capacity strategically focused to meet high demand for biologics for PFS and EZ-fill® cartridges to satisfy market demand • Custo
Slide 8: Solid Momentum As We Start 2026
Solid Momentum As We Start 2026 • Delivered results in line with our expectations, demonstrating the resilience of our business model • BDS Segment performance remains very strong, supported by continued HVS demand and the progress of our projects in Latina and Fishers • Engineering Segment results
Slide 9: Marco Dal Lago
x Marco Dal Lago Chief Financial Officer Q1 2026 Financial Results
Slide 10: Q1 2026: Financial Highlights
Q1 2026: Financial Highlights Q1 2026: Revenue Q1 2026: Margins (€ Million) HVS non-HVS growth at CC • Gross profit margin increased 30 bps to 27.5%, driven by − (i) expected improvements from Latina and Fishers (sites +7% remain margin-dilutive, but gaining operating leverage as 257 274 we scale vo
Slide 11: Q1 2026: Segment Trends
Q1 2026: Segment Trends Biopharmaceutical and Diagnostic Solutions (BDS) Segment Revenue increased 13% (16% at CC), driven by growth in HVS and other containment • Revenue from HVS grew 17% to €128.6 million, or approx. 52% of BDS revenue REVENUE 249 (€ Million) 221 • Revenue from other containment
Slide 12: Balance Sheet and Cash Flow Items
Balance Sheet and Cash Flow Items At Quarter-Ended March 31, 2026 Cash and Cash Equivalents € 111.7 M Net Debt € 337.7 M In the First Quarter of 2026 CAPEX € 67.6 M • Over 90% of Capex tied to growth In the First Quarter of 2026 Cash from operating activities + € 75.5 M Cash used in the purchase of
Slide 13: Reiterating FY 2026 Guidance
Reiterating FY 2026 Guidance FY 2026 Guidance Implied Growth Revenue € 1.260B - € 1.290B 6% to 9% Revenue at Constant Currency € 1.278B - € 1.308B 8% to 10% Adjusted DEPS* € 0.59 - € 0.63 8% to 16% Adjusted EBITDA* € 331.8M - € 346.9M 11% to 16% __________ *Adjusted operating profit margin, adjusted
Slide 14: Great Start To Fiscal 2026, with Continued Momentum
Great Start To Fiscal 2026, with Continued Momentum: Progress At Our New Sites And Increased Mix Of High-Value Solutions • Progress at our Latina and Fishers sites, and increased mix of HVS • Encouraged by initial margin improvement in the Engineering Segment, while remaining cautious given current
Slide 15: Thank You
Upcoming Conferences and Marketing Activities • Bank of America Global Healthcare Conference in Las Vegas, NV – May 12, 2026 • William Blair Growth Stock Conference in Chicago, IL – June 2, 2026 • Jefferies Healthcare Conference in New York, NY – June 4, 2026 Thank You Investor Relations Contacts Me
Slide 16: Reconciliation of Non-GAAP Financial Measures
Reconciliation of Non-GAAP Financial Measures This presentation contains non-GAAP financial measures. Please refer to the tables included in this presentation for a reconciliation of non-GAAP measures. Management monitors and evaluates our operating and financial performance using several non-GAAP f
Slide 17: Reconciliation of Non-GAAP Financial Measures (1/5)
Reconciliation of Non-GAAP Financial Measures (1/5) Reconciliation of Revenue to Constant Currency Revenue Reconciliation of EBITDA (Amounts in € millions) (Amounts in € millions) Biopharmaceutical For the three months Change ended March 31, and 2026 2025 % Diagnostic Three months ended March 31, 20
Slide 18: Reconciliation of Non-GAAP Financial Measures (2/5)
Reconciliation of Non-GAAP Financial Measures (2/5) Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Income Taxes, Net Profit, and Diluted EPS (Amounts in € millions, except per share data) Operating Income Diluted EPS Three months ended March 31, 2026 EBITDA Net Profit Profit Taxes
Slide 19: Reconciliation of Non-GAAP Financial Measures (3/5)
Reconciliation of Non-GAAP Financial Measures (3/5) Capital Employed As of March 31, As of December (Amounts in € millions) 2026 31, 2025 - Goodwill and intangible assets 86.5 86.8 - Right of use assets 15.2 12.4 - Property, plant and equipment 1,451.0 1,391.5 - Financial assets - investments FVTPL
Slide 20: Reconciliation of Non-GAAP Financial Measures (4/5)
Reconciliation of Non-GAAP Financial Measures (4/5) CAPEX Net (Debt) / Net Cash (Amounts in € millions) (Amounts in € millions) For the three months As of December Change As of March 31, ended March 31, 31, 2026 2025 2026 2025 € Non-current financial liabilities (323.8 ) (347.4 ) Addition to Propert
Slide 21: Reconciliation of Non-GAAP Financial Measures (5/5)
Reconciliation of Non-GAAP Financial Measures (5/5) Reconciliation of 2026 Guidance* Reported and Adjusted EBITDA, Operating Profit, Net Profit, Diluted EPS (Amounts in € millions, except per share data) Operating Diluted EPS Revenue EBITDA Net Profit Profit (EUR) 1,260.0 - Reported 1,290.0 317.7 -